-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the Pacific Securities Research Report, Yuyue Medical's 26Q3 may have reached an inflection point, and both revenue and profit were corrected year-on-year. Net profit to mother for the first three quarters was 1,131 million yuan, down 22.83% year on year; Q3 net profit to mother was 288 million yuan, up 9.55% year on year. The respiratory treatment sector returned to growth, and non-invasive ventilators were approved by the US FDA; dual dosage of blood sugar and first aid, and wearability and AI extended the growth curve. The first aid sector benefited from increasingly improved product matrices, the implementation of registration certificates in many overseas locations, and the effective expansion of marketing channels. The business continued to grow rapidly in the first three quarters. In the field of wearables and AI, the company has launched the smart health ring R3 and the smart blood pressure watch Watcha1. The wrist dynamic blood pressure recorder was certified in July; it comprehensively promoted the construction of a “hardware+software+data” health management ecosystem, and plans to promote the implementation of AI applications such as wearable and metabolic management products in the future. The current stock price PE is 19/17/14 times, respectively. Maintain a “buy” rating.

Zhitongcaijing·11/17/2026 07:25:03
Listen to the news
According to the Pacific Securities Research Report, Yuyue Medical's 26Q3 may have reached an inflection point, and both revenue and profit were corrected year-on-year. Net profit to mother for the first three quarters was 1,131 million yuan, down 22.83% year on year; Q3 net profit to mother was 288 million yuan, up 9.55% year on year. The respiratory treatment sector returned to growth, and non-invasive ventilators were approved by the US FDA; dual dosage of blood sugar and first aid, and wearability and AI extended the growth curve. The first aid sector benefited from increasingly improved product matrices, the implementation of registration certificates in many overseas locations, and the effective expansion of marketing channels. The business continued to grow rapidly in the first three quarters. In the field of wearables and AI, the company has launched the smart health ring R3 and the smart blood pressure watch Watcha1. The wrist dynamic blood pressure recorder was certified in July; it comprehensively promoted the construction of a “hardware+software+data” health management ecosystem, and plans to promote the implementation of AI applications such as wearable and metabolic management products in the future. The current stock price PE is 19/17/14 times, respectively. Maintain a “buy” rating.